Tonix appoints former EVP James Hunter to Board; 7,740 option grant at $34.54

Tonix Pharmaceuticals Holding Corp.

Appointment effective June 12, 2025; Hunter served as EVP Commercial from June 2023 to Dec 2024.
Received 7,740 stock options at $34.54, vesting at 2026 annual shareholder meeting.
Hunter led launch of Tonix Medicines and migraine asset acquisitions Zembrace and Tosymra.
Board addition strengthens commercial expertise ahead of potential TNX-102 SL fibromyalgia launch; PDUFA Aug 15, 2025.
Not independent under NASDAQ standards due to prior consulting and employment compensation.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

James Hunter

member of the Board

TNXP · Tonix Pharmaceuticals Holding Corp.

Effective: 2025-06-12
Filed: June 13, 2025, 7:59 PM ET

appointed James Hunter as a member of the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James Hunter was appointed as member of the Board at Tonix Pharmaceuticals Holding Corp..

Action: appointed
Role: member of the Board

Exact text from the filing

appointed James Hunter as a member of the Board

View on SEC.gov

Tonix Pharmaceuticals Holding Corp. filing history →

Source: SEC EDGAR

accession 0001999371-25-007734

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.